-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target

Benzinga·11/13/2026 12:34:37
Listen to the news
Leerink Partners analyst Lili Nsongo upgrades enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Outperform and announces $5 price target.